Irbesartan Ipca Laboratories Uk (Irbesartan)

Irbesartan is an angiotensin II receptor blocker that acts on the renin‑angiotensin system to control blood pressure and renal outcomes.

• Hypertension: lowers systolic and diastolic pressure, reducing cardiovascular risk in adults.
• Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes.
• Cardiovascular risk reduction: used as part of therapy to lower the chance of stroke and heart attack in hypertensive patients.

• Irbesartan selectively blocks angiotensin II type 1 (AT1) receptors on vascular smooth muscle and adrenal tissue, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. This results in vasodilation, reduced sodium and water retention, and ultimately lower arterial pressure and decreased strain on the kidneys.

Irbesartan is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Dizziness: feeling light‑headed, especially after the first doses.
• Headache: mild to moderate intensity.
• Fatigue: unusual tiredness without exertion.
• Upper respiratory tract infection: cold‑like symptoms.
• Hyperkalemia: elevated blood potassium levels.
• Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects

• Angioedema: swelling of the face, lips, tongue or throat, which can be life‑threatening.
• Acute renal failure: sudden loss of kidney function, particularly in patients with pre‑existing renal disease.
• Severe hypotension: marked drop in blood pressure causing fainting.
• Hepatotoxicity: liver injury presenting with jaundice or elevated enzymes.
• Myocardial infarction: rare reports of heart attack.
• Anaphylactic reaction: severe allergic response requiring emergency care.

Before initiating Irbesartan, clinicians should evaluate several safety factors.

• Monitor blood pressure: adjust dose to achieve target levels.
• Assess renal function: check serum creatinine and potassium before and during therapy.
• Avoid in severe hepatic impairment: use only if benefits outweigh risks.
• Pregnancy: contraindicated in the second and third trimesters due to fetal toxicity.
• Drug interactions: review concomitant medications, especially potassium‑sparing agents.
• Store at room temperature: keep in the original container, protect from moisture and light.

Irbesartan can interact with several medicines, requiring careful management.

Major Interactions (Avoid)

• Potassium‑sparing diuretics: increase risk of hyperkalemia.
• ACE inhibitors: additive risk of angioedema and renal dysfunction.
• Aliskiren in diabetic patients: heightened renal adverse events.
• NSAIDs: may blunt antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely)

• Lithium: Irbesartan can raise lithium concentrations, risking toxicity.
• Cyclosporine: may cause increased serum creatinine.
• Thiazide diuretics: can enhance hypotensive response, requiring dose adjustment.